BioSpace News Archive

Vaxxel SAS, a French start-up, developing vaccines against respiratory viral infections, announces the acquisition of Transgene’s proprietary DuckCelt®-T17 cell line.

Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, has been awarded a Good Manufacturing Practices certification by the Finnish Medicines Agency, FIMEA.

Progression free survival at the 9-month follow-up is tracking in line with previously published data

Inositec, a pioneer in the development of life-saving small molecule drugs based on the natural compound inositol hexaphosphate, announced that the U.S. Patent and Trademark Office has issued a patent covering its platform of inositol phosphate analogs and specifically INS-3001, an inhibitor of pathological soft tissue calcification.

Masimo announced the findings of a study published in the Journal of Anesthesiology and Reanimation Specialists’ Society in which researchers compared two methods of intraoperative fluid management during orthopedic spinal surgery, including Masimo PVi®.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 525,000 shares of BioCryst common stock on April 30, 2020 as inducements material to each employee entering into employment with BioCryst.

CONMED Corporation announced that Curt R. Hartman, President and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the BofA Securities Virtual Healthcare Conference at 9:40 a.m. ET on Tuesday, May 12, 2020.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs post-market on May 11, 2020.

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that the distribution date for the previously announced distribution to our stockholders of shares of Hoth Therapeutics, Inc. (“Hoth”) will not be taking place today, May 4, 2020, because of the requirement that the shares be registered prior to distribution.

Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its first quarter 2020 financial results on Thursday, May 14, 2020, after the market close.